臨床研究等提出・公開システム

A Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of LY4006895 in Healthy Volunteers and Patients With Early Symptomatic AD (J5K-MC-OQAA)

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) (J5K-MC-OQAA)

Hosoya Naofumi

Eli Lilly Japan K.K.

5-1-28, Isogamidori, Chuo-ku, Kobe, Hyogo

LTG_CallCenter@lists.lilly.com

Trial Guide Call Center

Eli Lilly Japan K.K.

5-1-28, Isogamidori, Chuo-ku, Kobe, Hyogo

+81-120-023-812

LTG_CallCenter@lists.lilly.com

Pending

June. 26, 2026

Interventional

randomized controlled trial

double blind

placebo control

parallel assignment

basic science

For Part A and Part B
-Have a body mass index (BMI) within the range 18 to 40 kilogram per square meter (kg/m2)

For Part A:
-Are overtly healthy as determined by medical evaluation. Rescreening is not allowed in this study

For Part B:
Have early symptomatic AD, as defined by:
-Gradual and progressive change in memory function for at least 6 months, as reported by the participant or informant
-A Mini-Mental State Exam (MMSE) score of 18 to 30 at screening
-A Clinical Dementia Rating (CDR) global score of 0.5 to 1.0 (inclusive), with a memory box score greater than or equal to 0.5 at screening
-Have up to 2 reliable study partners who are in frequent contact with the participant (defined as at least 10 hours per week), one of whom at any one occasion: will accompany the participant to the study visits, will be available by telephone at designated times, and will provide a separate written informed consent to participate

-Current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, neurologic (MAD: other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the participant's ability to complete the study; or has a life expectancy of less than 24 months
-Have screening hemoglobin (Hb) less than 12 grams per deciliter (g/dL) or evidence of iron-deficiency (ferritin less than 30 nanograms per milliliter (ng/mL), or presence/history of hemoglobinopathy
-Are, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide
-Regularly use known drugs of abuse and/or show positive findings on urinary drug screening that cannot be explained by regular concomitant medications
-Have previous exposure to any anti-tau therapy
-Are pregnant or intend to become pregnant or to breastfeed during the study

For Part B:
-Have a current exposure to an amyloid targeted therapy. Prior exposure to amyloid targeted therapies greater than 1 year from the last dose may be permitted at the discretion of the investigator and in consultation with the sponsor. A listing of amyloid targeted therapies will be provided
-Have a sensitivity to florataucipir 18F
-Have contraindication to magnetic resonance imaging (MRI) including claustrophobia or the presence of contraindicated metal (ferrogmagnetic) implants/cardiac pacemaker

Both

Alzheimer Disease
Healthy

DRUG: LY4006895
Administered IV
DRUG: Placebo
Administered IV

(Study Arms)
Experimental: LY4006895 of Part A (SAD)
Single-ascending doses of LY4006895 administered intravenously (IV)
Interventions:
Drug: LY4006895

Placebo Comparator: Placebo Part A
Placebo administered IV
Interventions:
Drug: Placebo

Experimental: LY4006895 of Part B (MAD)
Multiple-ascending doses of LY4006895 will be administered IV
Interventions:
Drug: LY4006895

Placebo Comparator: Placebo Part B
Placebo administered IV
Interventions:
Drug: Placebo

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Discontinuations due to Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration [Time Frame: Baseline to Study Completion (Up to 61 Weeks)]
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module

+81-562-46-2311

April. 21, 2026

No

United States